Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

LeapFrog Investments: Goodlife Pharmacy, East Africa’s Leading Pharmacy Brand Named ‘Portfolio Company of the Year’ at the 2018 Private Equity Africa GP & Advisor Awards

LeapFrog Investments
Posted on: 15 Jun 18
LeapFrog Investments: Goodlife Pharmacy, East Africa’s Leading Pharmacy Brand Named ‘Portfolio Company of the Year’ at the 2018 Private Equity Africa GP & Advisor Awards

PR Newswire

LAGOS, Nigeria, June 15, 2018

LAGOS, Nigeria, June 15, 2018 /PRNewswire/ --

Company is on target to rise to address the health needs of 5.5 million emerging consumers  

  • Goodlife Pharmacy, designated 'Portfolio Company of the Year' at the Private Equity Africa GP & Advisor Awards 2018
  • One year on from a $22 million investment by LeapFrog Investments, Goodlife has emerged as East Africa's largest pharmacy brand, growing from 19 to 38 stores
  • LeapFrog utilises a qualitative and quantitative research-led strategy to inform product and strategic expansion. This approach is unique to the East African market
  • Goodlife is set to increase its footprint to 100 stores over the next five years

LeapFrog Investments has won the 'Portfolio Company of the Year' Award at the Private Equity Africa GP & Advisor Awards 2018, for its investment in Goodlife Pharmacy, the leading East African pharmacy brand. Goodlife was recognised for building a large and trusted brand, associated with quality medicines and traceable supply chains, with profound impact. The popularity of the brand with customers has enabled rapid geographic expansion, with an increase from 19 to 38 stores in only one year, delivering strong unit economics and profitability.

     (Logo: )

     (Photo: )

Goodlife's portfolio of products and services, unparalleled for the region, include nutritional services, telehealth, medicine dispensing, and beauty and wellness services. In this way, Goodlife plays an active role in the health management and provision of high grade health services, on par with many leading Western pharmacies, and already reaches more than 1 million East Africans.

A shift in disease burden from acute to chronic illnesses such as Diabetes, Hypertension, and Cardio Vascular Disease is driving a need for the provision of long-term, non-hospital care on a distributed basis at the community level. Goodlife has built a business to enable ongoing management of these conditions, at the pharmacy level with plans to expand to 100 stores by 2020, and to serve 5.5 million people over the next five years.

Dr Felix Olale, Partner of LeapFrog Investments, commented: "The healthcare gap in Africa presents a long-term opportunity for LeapFrog to innovate and help to create a sustainable health infrastructure across the region. By putting consumer insights and needs at the heart of our strategy, we are building a business at a grass roots level that is both accessible and affordable to those who need it most. Goodlife is the greatest example of this approach in action."

Goodlife recently added laboratory testing services to its offering, with an agreement with Lancet Labs. In-store testing is not only convenient; having internationally accredited lab services integrated into the pharmacies addresses the important challenge of unlicensed medical labs springing up across the region, resulting in incorrect diagnosis and treatment of patients.  

The high-level commercial and operational standards established for Goodlife since LeapFrog's investment have enabled the company to attract exceptional leaders to the business from both healthcare and retail sectors. In 2018, Amaan Khalfan joined Goodlife as CEO from the leadership team at the Aga Khan University Hospital, one of the leading healthcare networks in Sub-Saharan Africa.

Goodlife is well positioned for future growth, in a growing market: the IFC estimates that consumer spending on healthcare in Sub-Saharan Africa will double over the next ten years.

With over 10 years investing in healthcare and financial services, LeapFrog's healthcare strategy is focused on bridging the gap between a growing consumer demand for healthcare services and the limited ability to pay for these services. By investing in both insurers and providers of healthcare services, LeapFrog aims to reduce the out of pocket expense burden for consumers, thereby increasing the overall impact on their welfare. 

About LeapFrog Investments 

LeapFrog invests in extraordinary businesses in Africa and Asia. We partner with their leaders to achieve leaps of growth, profitability and impact. LeapFrog companies now operate across 149 markets reaching 130 million people with healthcare and financial services. Over 110 million of those are emerging consumers, often accessing healthcare, insurance, savings, pensions and credit for the first time. LeapFrog companies provide jobs and livelihoods to 120,000 people. These companies have grown on average by nearly 40 per cent per annum since LeapFrog's investment. LeapFrog was recently named by Fortune as one of the top five companies changing the world, alongside Apple and Novartis, becoming the first private equity firm every to be listed.

For further information, please contact: 

Greenbrook Communications    
James Madsen / Gina Bell / Ed Jenkins

PR Newswire

Last updated on: 15/06/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.